Beth Y Karlan

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women
    Beth Y Karlan
    Authors Affiliations Cedars Sinai Medical Center, Los Angeles
    Cancer Epidemiol Biomarkers Prev 23:1383-93. 2014
  2. ncbi request reprint POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer
    Beth Y Karlan
    Women s Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA Electronic address
    Gynecol Oncol 132:334-42. 2014
  3. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
  4. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  5. doi request reprint Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
    Beth Y Karlan
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 30:362-71. 2012
  6. ncbi request reprint Evolution through intelligent design
    Beth Y Karlan
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA 90048 1865, USA
    Gynecol Oncol 102:1-4. 2006
  7. ncbi request reprint ERCC5 is a novel biomarker of ovarian cancer prognosis
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute, David Geffen School of Medicine, University of California at Los Angeles, CA 90048, USA
    J Clin Oncol 26:2952-8. 2008
  8. ncbi request reprint BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
    Ilana Cass
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Los Angeles, Cedars Sinai Medical Centers, CA 90048, USA
    Obstet Gynecol 106:1327-34. 2005
  9. ncbi request reprint Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Breast Cancer Res Treat 105:139-55. 2007
  10. doi request reprint Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers
    Andrew J Li
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 160W, Los Angeles, CA 90048, USA
    Gynecol Oncol 116:105-8. 2010

Detail Information

Publications86

  1. pmc Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women
    Beth Y Karlan
    Authors Affiliations Cedars Sinai Medical Center, Los Angeles
    Cancer Epidemiol Biomarkers Prev 23:1383-93. 2014
    ..Serum markers are used before pelvic imaging to improve specificity and positive predictive value (PPV) of ovarian cancer multimodal screening strategies...
  2. ncbi request reprint POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer
    Beth Y Karlan
    Women s Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA Electronic address
    Gynecol Oncol 132:334-42. 2014
    ..To identify molecular prognosticators and therapeutic targets for high-grade serous epithelial ovarian cancers (EOCs) using genetic analyses driven by biologic features of EOC pathogenesis...
  3. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
    ..2)...
  4. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  5. doi request reprint Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
    Beth Y Karlan
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 30:362-71. 2012
    ....
  6. ncbi request reprint Evolution through intelligent design
    Beth Y Karlan
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA 90048 1865, USA
    Gynecol Oncol 102:1-4. 2006
  7. ncbi request reprint ERCC5 is a novel biomarker of ovarian cancer prognosis
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute, David Geffen School of Medicine, University of California at Los Angeles, CA 90048, USA
    J Clin Oncol 26:2952-8. 2008
    ..Gene expression analyses were performed through microarray experiments. Candidate genes were tested for independent effects on survival using Cox proportional hazards models, Kaplan-Meier survival curves, and the log-rank test...
  8. ncbi request reprint BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
    Ilana Cass
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Los Angeles, Cedars Sinai Medical Centers, CA 90048, USA
    Obstet Gynecol 106:1327-34. 2005
    ..To compare clinical and histologic features between fallopian tube cancers in women with germline BRCA mutations and sporadic cases...
  9. ncbi request reprint Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Breast Cancer Res Treat 105:139-55. 2007
    ..Thus, unmasking of epigenetic silencing in breast cancer enabled us to discover a large number of candidate tumor suppressor genes. Further analysis suggested a role of one of these genes, PTCH, in breast cancer tumorigenesis...
  10. doi request reprint Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers
    Andrew J Li
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 160W, Los Angeles, CA 90048, USA
    Gynecol Oncol 116:105-8. 2010
    ..We hypothesized that AR CAG allele length is a modifier of clinical outcome in BRCA1/2 mutation positive women with ovarian cancer...
  11. pmc Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas
    Christine S Walsh
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Clin Cancer Res 14:7645-51. 2008
    ..The importance of the BRCA gene products in maintaining genomic stability led us to hypothesize that BRCA-associated and sporadic ovarian cancers would have distinctive genetic profiles despite similarities in histologic appearance...
  12. ncbi request reprint Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas
    Andrew J Li
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Gynecol Oncol 109:220-5. 2008
    ..We hypothesize short AR allelotypes promote aggressive ovarian cancer phenotype through modulation of epidermal growth factor receptor (EGFR) signaling...
  13. ncbi request reprint Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis
    Min Zhu
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA
    Mol Cancer Ther 10:1500-8. 2011
    ..The data suggest that blocking periostin expression may be a novel approach for treating the subset of invasive ovarian tumors that overexpress periostin protein...
  14. doi request reprint Periostin promotes ovarian cancer angiogenesis and metastasis
    Min Zhu
    Division of Hematology Oncology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
    Gynecol Oncol 119:337-44. 2010
    ..In the present study, we investigated PN expression status in a large cohort of ovarian tumors with the focus on biological influence of PN related on ovarian tumor angiogenesis and metastasis...
  15. ncbi request reprint Hereditary ovarian cancer--assessing risk and prevention strategies
    James C Pavelka
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Obstet Gynecol Clin North Am 34:651-65, vii-viii. 2007
    ..In all mutation carriers who have completed or do not desire childbearing, prophylactic bilateral salpingo-oophorectomy must be strongly considered...
  16. doi request reprint Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells
    Barbie Taylor-Harding
    Women s Cancer Research Institute and Division of Gynecologic Oncology, Burns and Allen Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Gynecol Oncol 119:549-56. 2010
    ..We hypothesized that statins have a cytotoxic effect and that the combination of fluvastatin and cisplatin inhibits cellular proliferation in epithelial ovarian cancer cells...
  17. ncbi request reprint Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer
    Amer K Karam
    Division of Gynecologic Oncology, The David Geffen School of Medicine at UCLA, Los Angeles, CA 9095, USA
    Gynecol Oncol 114:246-52. 2009
    ..We sought to examine the impact of EDR assay-guided therapy on the outcome of patients with EOC in the primary and recurrent settings...
  18. doi request reprint Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein
    Daniel R Scoles
    Women s Cancer Research Institute and Division of Gynecologic Oncology, CSMC Burns and Allen Research Institute, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA, USA
    Gynecol Oncol 116:109-16. 2010
    ..Here we investigate the direct effects of low density lipoprotein (LDL) and oxidized LDL (oxLDL) on proliferation and the inhibitory effects of fluvastatin and a liver X receptor (LXR) agonist...
  19. ncbi request reprint Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology
    Andrew J Li
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 160W, Los Angeles, CA 90048, USA
    Gynecol Oncol 107:420-3. 2007
    ..We have hypothesized that the combination of these factors further manifests an aggressive ovarian cancer phenotype...
  20. ncbi request reprint Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest
    Ido Wolf
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Oncol 30:1529-37. 2007
    ..Our data suggest that HNK is a systemically available, non-toxic inhibitor of breast cancer growth and should be examined for clinical applications...
  21. doi request reprint Obesity-associated adipokines correlate with survival in epithelial ovarian cancer
    Elena S Diaz
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 280W, Los Angeles, CA 90048, USA
    Gynecol Oncol 129:353-7. 2013
    ..Adipocytes secrete leptin and adiponectin, and the leptin to adiponectin (L:A) ratio is correlated with poor survival in other malignancies. We hypothesized that the L:A ratio is associated with survival in women with EOC...
  22. pmc Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas
    Barbara Norquist
    University of Washington Medical Center, Department of Obstetrics and Gynecology, Box 356460, Seattle, WA, USA
    J Clin Oncol 29:3008-15. 2011
    ..We assessed primary and recurrent BRCA1/2-mutated ovarian carcinomas to define the frequency of secondary mutations and correlate these changes with clinical outcomes...
  23. doi request reprint Impact of beta blockers on epithelial ovarian cancer survival
    Elena S Diaz
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gynecol Oncol 127:375-8. 2012
    ..We sought to determine the association between beta blocker use and epithelial ovarian cancer (EOC) disease progression and survival...
  24. ncbi request reprint FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Cancer 120:1013-22. 2007
    ..Yet, FOXA1 expression was noted in a subset of the ER-negative tumors. Taken together, our findings suggest a growth inhibitory role for FOXA1, and identify it as a novel, potential prognostic factor in breast cancer...
  25. pmc Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening
    Christine S Walsh
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gynecol Oncol 116:516-21. 2010
    ..e. synchronous endometrial and ovarian cancer). Our study aims to estimate the prevalence of LS in these two populations...
  26. doi request reprint Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?
    Ilana Cass
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gynecol Oncol 117:27-31. 2010
    ..Risk-reducing bilateral salpingo-oophorectomy (RRSO) is an effective option for women with BRCA mutations however there is limited information as to how much tubal epithelium remains after RRSO...
  27. ncbi request reprint Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma
    Andrew J Li
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Cancer Res 9:3667-73. 2003
    ..Exon 1 of the AR gene contains a polymorphic (CAG)(n) sequence whose length is inversely correlated with transcriptional activity...
  28. doi request reprint Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival
    Joshua G Cohen
    Division of Gynecologic Oncology, Women s Cancer Program, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 280W, Los Angeles, CA 90048, USA
    Gynecol Oncol 132:556-9. 2014
    ..Here, we sought to determine the impact of elevated platelet count at time of secondary cytoreductive surgery (SCS) for recurrent disease...
  29. ncbi request reprint Improved survival in women with BRCA-associated ovarian carcinoma
    Ilana Cass
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center and University of California Los Angeles School of Medicine, Los Angeles, California 90048, USAA
    Cancer 97:2187-95. 2003
    ..The objective of this study was to determine the clinical characteristics, treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with hereditary ovarian carcinoma...
  30. ncbi request reprint Effect of cigarette smoking on epithelial ovarian cancer survival
    Yevgeniya J M Ioffe
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Reprod Med 55:346-50. 2010
    ..To determine associations between smoking and survival in patients with ovarian cancer...
  31. ncbi request reprint Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, California 90048, USA
    Cancer 118:689-97. 2012
    ..The objective of this study was to determine whether single-nucleotide polymorphisms (SNPs) in NER pathway genes could be markers of platinum response in ovarian cancer...
  32. ncbi request reprint Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome
    Amer K Karam
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Gynecol Oncol 104:377-80. 2007
    ..We sought to evaluate the impact of TCS on survival and to determine predictors of optimal tertiary resection...
  33. ncbi request reprint A human ovarian carcinoma murine xenograft model useful for preclinical trials
    John C Elkas
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gynecol Oncol 87:200-6. 2002
    ..To establish a murine xenograft model of human ovarian carcinoma...
  34. ncbi request reprint Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT
    Daniel R Scoles
    Women s Cancer Research Institute at Samuel Oschin Comprehensive Cancer Institute and Division of Gynecologic Oncology, CSMC Burns and Allen Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gynecol Oncol 104:120-8. 2007
    ..We describe a new ovarian cancer cell line that arose from primary culture of a stage IC, grade III ovarian carcinoma, designated CSOC 882...
  35. ncbi request reprint Effect of obesity on survival in epithelial ovarian cancer
    James C Pavelka
    Cedars Sinai Medical Center, Women s Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA
    Cancer 107:1520-4. 2006
    ..The current study attempted to determine the influence of excess body weight on ovarian cancer survival, disease progression, and clinicopathologic factors...
  36. ncbi request reprint The prognostic significance of thrombocytosis in uterine papillary serous carcinomas
    Dimitry L Lerner
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 160W, Los Angeles, CA 90048, USA
    Gynecol Oncol 104:91-4. 2007
    ..In light of the similarities between uterine papillary serous carcinomas (UPSC) and EOC, we sought to determine the incidence of thrombocytosis in UPSC and examine associations with clinico-pathologic features and survival...
  37. doi request reprint Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival
    Elena S Diaz
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 160W, Los Angeles, CA 90048, USA Electronic address
    Gynecol Oncol 131:541-5. 2013
    ..To determine the impact of venous thromboembolism (VTE) during primary treatment of ovarian clear cell carcinoma (OCCC) on survival...
  38. ncbi request reprint Functional domains of CCN1 (Cyr61) regulate breast cancer progression
    James O'Kelly
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Oncol 33:59-67. 2008
    ....
  39. doi request reprint CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, CA 90048, USA
    Gynecol Oncol 121:249-52. 2011
    ..We hypothesized that a shorter time interval between CA125 elevation and SCS correlates with a higher likelihood of optimal resection among eligible patients...
  40. ncbi request reprint Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures
    Andrew J Li
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Obstet Gynecol 189:22-7. 2003
    ..Epidemiologic data suggest that the malignant transformation of ovarian epithelium may be linked to altered steroid hormone homeostasis...
  41. ncbi request reprint 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Cancer Res 66:7818-23. 2006
    ..Our results indicate for the first time that 15-PGDH may be a novel tumor suppressor gene in breast cancer, and suggest that this enzyme can modulate the ER pathway...
  42. ncbi request reprint AIB1 polymorphisms predict aggressive ovarian cancer phenotype
    Andrew J Li
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Suite 160W, Los Angeles, CA 90048, USA
    Cancer Epidemiol Biomarkers Prev 14:2919-22. 2005
    ..We hypothesized that genotypic variations in the androgen-signaling pathway promote aggressive epithelial ovarian cancer biology, and sought to examine the effect of AIB1 genotype on clinical outcome...
  43. pmc Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
    Elizabeth M Swisher
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
    Cancer Res 68:2581-6. 2008
    ..Our results suggest that secondary mutations in BRCA1 can mediate resistance to platinum in BRCA1-mutated ovarian tumors...
  44. ncbi request reprint Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling
    Rae Lynn Baldwin
    Division of Gynecologic Oncology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Cancer Res 63:1413-9. 2003
    ..These data suggest that TGF-beta/Smad signaling is blocked downstream of Smad complex formation or that an alternate signaling pathway other than TGF-beta/Smad may transmit TGF-beta-induced cell cycle arrest in the ovarian epithelium...
  45. doi request reprint Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas
    Deborah A Zajchowski
    The Clearity Foundation, La Jolla, CA, USA
    Mol Cancer Ther 11:492-502. 2012
    ..Expression of these and other candidate response biomarkers must be evaluated in much larger studies and, if confirmed, support the need for profiling of recurrent tumor specimens in future clinical trials...
  46. doi request reprint Post treatment surveillance of type II endometrial cancer patients
    Mae Zakhour
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 280W, Los Angeles, CA 90048, USA
    Gynecol Oncol 131:609-12. 2013
    ..Our objective was to determine the types of post treatment surveillance tests performed in our institution and the efficacy of these tests in detecting recurrence in type II endometrial cancer patients...
  47. doi request reprint Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers
    Andrew J Li
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Gynecol Oncol 116:78-81. 2010
    ..We have hypothesized that statins influence ovarian cancer outcome through alteration of lipoprotein profiles, and sought to determine correlations between lipoprotein levels and survival in women with advanced stage disease...
  48. ncbi request reprint Impact of statin therapy on survival in epithelial ovarian cancer
    R Geoffrey Elmore
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Gynecol Oncol 111:102-5. 2008
    ..We sought to determine the association between use of statins and epithelial ovarian cancer survival, disease progression, and clinico-pathologic factors...
  49. doi request reprint Quality of care in advanced ovarian cancer: the importance of provider specialty
    Cheryl Mercado
    Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6904, USA
    Gynecol Oncol 117:18-22. 2010
    ..We examined whether surgeon specialty impacts quality of life (as proxied by presence of ostomy) and overall survival for women with advanced ovarian cancer...
  50. ncbi request reprint The prognostic significance of thrombocytosis in epithelial ovarian carcinoma
    Andrew J Li
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Gynecol Oncol 92:211-4. 2004
    ..Thrombocytosis (platelet counts >400 x 10(9)/l) has been identified as a poor prognostic factor in many cancers. Platelet-secreted factors may contribute to metastasis, invasion, and primary tumor growth...
  51. ncbi request reprint Ovarian preservation in stage I low-grade endometrial stromal sarcomas
    Andrew J Li
    Department of Obstetrics Gynecology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Obstet Gynecol 106:1304-8. 2005
    ..To examine the impact of ovarian preservation in a case-control study of women with stage I low-grade endometrial stromal sarcomas...
  52. ncbi request reprint BRCA1 promoter methylation predicts adverse ovarian cancer prognosis
    Jing Wang Chiang
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, 160W, Los Angeles, CA 90048, USA
    Gynecol Oncol 101:403-10. 2006
    ..To compare the clinical outcome of ovarian cancer patients whose tumors contain BRCA1 genes silenced by promoter hypermethylation to patients with germline BRCA1 mutations and to patients with wild-type BRCA genes...
  53. doi request reprint Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?
    Nicole D Fleming
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars Sinai Women s Cancer Research Institute, Los Angeles, CA 90048, USA
    Gynecol Oncol 120:189-92. 2011
    ..The purpose of this study is to assess if age is an independent poor prognostic factor in endometrioid histologies...
  54. ncbi request reprint Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Women s Cancer Research Institute, David Geffen School of Medicine at UCLA, 8700 Beverly Boulevard, Suite 290W, Los Angeles, CA 90048, USA
    Gynecol Oncol 104:660-4. 2007
    ..The objective of this study was to examine the association between SNP309 and sporadic endometrial cancer risk...
  55. ncbi request reprint The role of genetic testing for cancer susceptibility in gynecologic practice
    Beth Y Karlan
    Women s Cancer Research Institute, Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of Los Angeles, Los Angeles, California 90048, USA
    Obstet Gynecol 110:155-67. 2007
    ..Practical applications of genetic testing for cancer susceptibility have the ability to reduce the burden of hereditary cancers by saving lives, decreasing medical morbidities, and reducing psychological stress...
  56. ncbi request reprint Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility
    Lindsay Gillan
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Cancer Res 62:5358-64. 2002
    ..We propose PN functions as a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins to support adhesion and migration of ovarian epithelial cells...
  57. ncbi request reprint A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
    Richard E Buller
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1009, USA
    Cancer Gene Ther 9:553-66. 2002
    ..p.) alone and sequentially in combination with platinum-based chemotherapy, of patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer containing aberrant or mutant p53...
  58. pmc Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers
    De Chen Lin
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 110:6109-14. 2013
    ..These results suggest that although targeted by genomic homozygous microdeletions, PDE4D functions as a tumor-promoting factor and represents a unique targetable enzyme of cancer cells...
  59. ncbi request reprint Ovarian cancer: the duplicity of CA125 measurement
    Amer K Karam
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Nat Rev Clin Oncol 7:335-9. 2010
    ....
  60. ncbi request reprint Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer
    Allison E Axtell
    University of California Los Angeles UCLA Medical Center, Los Angeles, CA, USA
    J Clin Oncol 25:384-9. 2007
    ..Reciprocally cross validate the predictors identified with those from two previously published cohorts from institutions B and C...
  61. ncbi request reprint Surgical advances in the treatment of ovarian cancer
    Andrew J Li
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Hematol Oncol Clin North Am 17:945-56. 2003
    ..Although laparoscopy may be feasible in staging women with disease apparently limited to an ovary, further studies are necessary before it can be considered routinely as an alternative to standard laparotomy...
  62. pmc Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer
    Hui Shen
    USC Epigenome Center, Keck School of Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Nat Commun 4:1628. 2013
    ..These findings underscore distinct mechanisms driving different epithelial ovarian cancer histological subtypes...
  63. ncbi request reprint Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies
    John C Elkas
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Walter Reed Army Medical Center, Room 6762, Building 2, 6900 Georgia Avenue NW, Washington, D C 20307, USA
    Gynecol Oncol 97:685-92. 2005
    ..As an alternative, a more limited resection with urinary tract reconstruction using ileum for interposition or augmentation may allow for the preservation of urethral voiding...
  64. doi request reprint Molecular signatures of ovarian cancer: from detection to prognosis
    Christine S Walsh
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Diagn Ther 14:13-22. 2010
    ..In this review, we discuss the current state of biomarker development for the early detection of ovarian cancer and explore the continuing challenges to realizing this goal...
  65. ncbi request reprint Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature
    Alexander Liede
    Women s Cancer Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite 290W, Los Angeles, CA 90048, USA
    J Clin Oncol 22:735-42. 2004
    ....
  66. ncbi request reprint The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer
    Christine H Holschneider
    Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1740, USA
    Clin Cancer Res 11:5756-63. 2005
    ....
  67. ncbi request reprint Chemotherapy in epithelial ovarian cancer
    Jing Wang
    Division of Gynecologic Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Boulevard, 160W, Los Angeles, CA 90048, USA
    Curr Womens Health Rep 2:20-6. 2002
    ..Investigations into novel chemotherapeutic agents and other biologic molecules have led to advances in the therapeutic armamentarium and have improved survival for women with ovarian cancer...
  68. ncbi request reprint Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells
    M Jane Arboleda
    Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, UCLA School of Medicine, Los Angeles, California 90095, USA
    Cancer Res 63:196-206. 2003
    ..Taken together, these data indicate that AKT2 mediates PI3-K-dependent effects on adhesion, motility, invasion, and metastasis in vivo...
  69. ncbi request reprint Gene expression in epithelial ovarian carcinoma
    Daniela Matei
    Department of Medicine, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, California, CA 90095, USA
    Oncogene 21:6289-98. 2002
    ..Use of cultured epithelial cells represents a novel strategy to study gene expression in a cell-type specific manner...
  70. pmc A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause
    Jeannette M Painovich
    Department of Medicine, Cedars Sinai Heart Institute, Los Angeles, CA 90048, USA
    Menopause 19:54-61. 2012
    ....
  71. ncbi request reprint ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1077, New York, New York 10021, USA
    Ann Surg Oncol 13:1296-321. 2006
    ..Clinical interventions have been formulated for mutation carriers within affected families. The primary interventions for mutation carriers of highly penetrant syndromes are surgical...
  72. ncbi request reprint Cancer incidence in a population of Jewish women at risk of ovarian cancer
    Alexander Liede
    Centre for Research in Women s Health, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    J Clin Oncol 20:1570-7. 2002
    ..To evaluate the incidence and clinical characteristics of ovarian and other cancers in a cohort of women at risk of developing ovarian cancer...
  73. ncbi request reprint Ovarian cancer screening
    Nicole Urban
    Cancer Prevention Research Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, MP 900, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
    Hematol Oncol Clin North Am 17:989-1005, ix. 2003
    ..Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods...
  74. ncbi request reprint Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC...
  75. ncbi request reprint The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
    Beth Y Karlan
    J Clin Oncol 25:1303-4. 2007
  76. ncbi request reprint Prognostic DNA methylation biomarkers in ovarian cancer
    Susan H Wei
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 12:2788-94. 2006
    ..Correspondingly, distinct combinations of methylated loci can function as biomarkers for numerous clinical correlates of ovarian and other cancers...
  77. ncbi request reprint Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions
    Johnathan M Lancaster
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Gynecol Oncol 107:159-62. 2007
    ..This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome...
  78. pmc Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
    Wataru Sakai
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Nature 451:1116-20. 2008
    ..Our results suggest that secondary mutations that restore the wild-type BRCA2 reading frame may be a major clinical mediator of acquired resistance to platinum-based chemotherapy...
  79. ncbi request reprint Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources: Committee on Government Reform United States House of Representatives
    Beth Y Karlan
    Gynecol Oncol 99:257-60. 2005
  80. ncbi request reprint Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer
    Jennifer A Byrne
    Molecular Oncology Laboratory, Oncology Research Unit, The University of Sydney Discipline of Paediatrics and Child Health, The Children s Hospital at Westmead, New South Wales, Australia
    Int J Cancer 117:1049-54. 2005
    ..TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number...
  81. ncbi request reprint ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes
    Jose G Guillem
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4642-60. 2006
    ....
  82. ncbi request reprint Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis
    Beth Y Karlan
    Gynecol Oncol 92:519-20. 2004
  83. ncbi request reprint Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer
    Antonio Santillan
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 600 N Wolfe Street, Phipps 281, Baltimore, MD 21287 1281, USA
    Gynecol Oncol 104:686-90. 2007
    ..To evaluate the feasibility and associated survival outcome of secondary cytoreductive surgery in patients with isolated lymph node recurrence of epithelial ovarian cancer...
  84. doi request reprint Improving efficiencies in translational science
    Beth Y Karlan
    Gynecol Oncol 108:461. 2008
  85. ncbi request reprint Can lifestyle influence genetics?
    Beth Y Karlan
    Nat Clin Pract Oncol 4:555. 2007
  86. ncbi request reprint The colon is a pelvic organ too: taking the Couric challenge
    Beth Y Karlan
    Obstet Gynecol 104:907-9. 2004